NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Forecast, Price & News $1.47 -0.10 (-6.37%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.44▼$1.6350-Day Range$1.45▼$3.1052-Week Range$1.39▼$8.25Volume940,419 shsAverage Volume778,199 shsMarket Capitalization$369.01 millionP/E RatioN/ADividend YieldN/APrice Target$6.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lyell Immunopharma MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside325.2% Upside$6.25 Price TargetShort InterestBearish17.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.08) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector571st out of 970 stocksPharmaceutical Preparations Industry271st out of 450 stocks 3.1 Analyst's Opinion Consensus RatingLyell Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Lyell Immunopharma has a forecasted upside of 325.2% from its current price of $1.47.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.22% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 28.3, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 5.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYEL. Previous Next 3.3 News and Social Media Coverage News SentimentLyell Immunopharma has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lyell Immunopharma this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders24.00% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.67% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($1.08) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lyell Immunopharma (NASDAQ:LYEL) StockLyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.Read More LYEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYEL Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comLyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 11, 2023 | marketwatch.comLyell Immunopharma Shares Up 8% on Cellares CollaborationSeptember 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 11, 2023 | finance.yahoo.comCellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformAugust 31, 2023 | finance.yahoo.comLyell Immunopharma to Participate in Upcoming Investor ConferencesAugust 29, 2023 | finance.yahoo.comAnalysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging HigherAugust 28, 2023 | msn.comJP Morgan cuts Lyell to neutral, pending data for cell therapy platformAugust 28, 2023 | msn.comJP Morgan Downgrades Lyell Immunopharma (LYEL)September 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 26, 2023 | msn.comLyell Immunopharma: Once Huge IPO Now Waiting For Clinical DataAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Lyell Immunopharma (LYEL)August 8, 2023 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023July 6, 2023 | lse.co.ukMaxCyte inks strategic platform license with Lyell ImmunopharmaJuly 6, 2023 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Lyell ImmunopharmaJuly 5, 2023 | finance.yahoo.comLyell Immunopharma Appoints Matthew Lang as Chief Business OfficerJune 16, 2023 | finance.yahoo.comWhy Shares of Lyell Immunopharma Jumped This WeekJune 7, 2023 | finance.yahoo.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceJune 1, 2023 | finance.yahoo.comEven after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past yearMay 5, 2023 | msn.comHC Wainwright & Co. Reiterates Lyell Immunopharma (LYEL) Buy RecommendationMay 5, 2023 | markets.businessinsider.comLyell Immunopharma (LYEL) Receives a Buy from H.C. WainwrightMay 4, 2023 | finance.yahoo.comLyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | msn.comLyell Immunopharma reports Q1 resultsMay 4, 2023 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023April 17, 2023 | finance.yahoo.comThere's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted RevenuesApril 13, 2023 | benzinga.comTORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology BiologicsMarch 27, 2023 | finance.yahoo.comAurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?March 26, 2023 | finance.yahoo.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stakeSee More Headlines Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Company Calendar Last Earnings8/08/2023Today9/30/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees274Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.25 High Stock Price Forecast$9.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+325.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-183,120,000.00 Net Margins-432.13% Pretax Margin-432.13% Return on Equity-26.40% Return on Assets-23.08% Debt Debt-to-Equity RatioN/A Current Ratio17.63 Quick Ratio17.63 Sales & Book Value Annual Sales$84.68 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.44Miscellaneous Outstanding Shares251,030,000Free Float190,781,000Market Cap$369.01 million OptionableNot Optionable Beta-1.38 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Richard D. Klausner M.D. (Age 71)Founder & Exec. Chairman Comp: $80kDr. Lynn Seely M.D. (Age 64)Ph.D., Pres, CEO & Director Comp: $430.69kMr. Charles W. Newton (Age 52)Chief Financial Officer Comp: $1.72MMr. Stephen J. Hill (Age 53)Chief Operating Officer Comp: $1.04MDr. Gary Lee Ph.D. (Age 46)Chief Scientific Officer Comp: $639.91kMs. Elizabeth Homans (Age 57)Consultant Comp: $1.99MProf. Stanley R. Riddell M.D.Founder & Scientific AdvisorDr. Crystal L. Mackall M.D.Founder & Scientific AdvisorNellie DilleryDirector of AccountingMs. Ellen RoseSr. VP of Communications & Investor RelationsMore ExecutivesKey CompetitorsEdgewise TherapeuticsNASDAQ:EWTXORIC PharmaceuticalsNASDAQ:ORICMarinus PharmaceuticalsNASDAQ:MRNSLiquidiaNASDAQ:LQDANurix TherapeuticsNASDAQ:NRIXView All CompetitorsInstitutional OwnershipCalifornia State Teachers Retirement SystemBought 103,178 shares on 8/21/2023Ownership: 0.067%Nuveen Asset Management LLCBought 143,569 shares on 8/16/2023Ownership: 0.235%Wells Fargo & Company MNBought 5,919 shares on 8/15/2023Ownership: 0.048%Royal Bank of CanadaBought 8,424 shares on 8/15/2023Ownership: 0.007%Citadel Advisors LLCBought 200 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions LYEL Stock - Frequently Asked Questions Should I buy or sell Lyell Immunopharma stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares. View LYEL analyst ratings or view top-rated stocks. What is Lyell Immunopharma's stock price forecast for 2023? 4 Wall Street research analysts have issued 1 year price objectives for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they predict the company's stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 325.2% from the stock's current price. View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts. How have LYEL shares performed in 2023? Lyell Immunopharma's stock was trading at $3.47 at the beginning of 2023. Since then, LYEL shares have decreased by 57.6% and is now trading at $1.47. View the best growth stocks for 2023 here. When is Lyell Immunopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our LYEL earnings forecast. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its earnings results on Tuesday, August, 8th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $3.31 million. Lyell Immunopharma had a negative trailing twelve-month return on equity of 26.40% and a negative net margin of 432.13%. When did Lyell Immunopharma IPO? (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO. What is Lyell Immunopharma's stock symbol? Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL." How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lyell Immunopharma's stock price today? One share of LYEL stock can currently be purchased for approximately $1.47. How much money does Lyell Immunopharma make? Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $369.01 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How many employees does Lyell Immunopharma have? The company employs 274 workers across the globe. How can I contact Lyell Immunopharma? The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com. This page (NASDAQ:LYEL) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.